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= Abstract =
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading cancer in 
Korea. During the last two decades, the incidence rate of primary liver cancer has shown a modest decrease, but 
its mortality rate has slightly increased. The incidence of HCC, according to age, peaks in the late sixth decade 
in men and in the early seventh decade in women. Hepatitis B virus (HBV) is the most important risk factor, which 
represents approximately 70% of all HCC, and hepatitis C virus (HCV) and alcohol are the next in order of major 
risk factors for the development of HCC in Korea. HBV-associated HCC occurs 10 years earlier than HCV-asso-
ciated HCC due to a more prolonged exposure to HBV, which is vertically transmitted almost from HBsAg-positive 
mother in HBV-endemic area. National Cancer Control Institute, which was reorganized in 2005, is now working 
for several national projects such as National Cancer Registration Program, National R&D Program for Cancer 
Control and National Cancer Screening Program. International collaboration for the clinico-epidemiologic research 
would be needed to provide the specific measures for managing HCC in diverse etiologic situations. Finally, the 
mechanisms of hepatitis virus-associated hepatocellular carcinogenesis might be clarified to provide insights into the 
advanced therapeutic and preventive approaches for HCC in Korea, where the majority of HCC originate from 
chronic HBV and HCV infections.
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Introduction 
Hepatocellular carcinoma (HCC) is the most serious malignant neoplasm which affects approximately over 
half a million persons worldwide. Korea is known to be a high endemic area of chronic hepatitis B virus (HBV) 
infection, and 5~6% of general populations are infected by HBV. In general, the geographic prevalence of HCC 
occurrence is based on the epidemiologic distribution and the natural history of HBV infection.1,2
In early 1980s, Hann et al3 presented that there were clustering of chronic carriers of HBV in families of 
Korean patients with HCC and emphasized the importance of preventive strategy for HBV infection in endemic 
areas. Since then, several articles4-6 have been reported in Korea, which suggest that chronic HBV infection is 
a major risk factor for HCC when considering the results of the evaluation for HBsAg and HBeAg status in 
patients with chronic hepatitis, liver cirrhosis or HCC, as well as control subjects. In 1990s, hepatitis C virus 
(HCV) was revealed to be another key risk factor for HCCs developing in patients with HBsAg-negative chronic 
liver disease, especially in those older than 60 years.7,8 Thereafter, anti-HCV-seropositive patients were also 
strongly recommended to be included in the surveillance program for the early detection of HCC.
This review will introduce the state of art in HCC in Korea including its comprehensive epidemiology, clin-
ical characteristics, treatment and prognosis.
Incidence
Primary liver cancer, which includes HCC, cholangiocarcinoma, Klatskin tumor, mixed HCC and chol-
angiocarcinoma, and hepatoblastoma in the order of their incidence, is the 3rd common leading malignancy in 
Korea following stomach and lung cancers.9,10 According to the statistics in 2005, the age-adjusted incidence 
rate of primary liver cancer is 44.9 per 100,000 persons in men, ranked 3rd following 66 for stomach and 48.5 
for lung cancer; 14.7 per 100,000 persons in women, ranked 7th following 37.3 for breast, 36.2 for thyroid, 
34.1 for stomach, 28.0 for colon, 17.9 for lung and 16.7 for cervix cancer during 2003~2005 (Fig. 1).11 The 
incidence of primary liver cancer tends to show a modest decrease from 1999 to 2005, indicating a different 
pattern from other cancers. These statistical informations were provided on the annual reports of National Cancer 
Registration Program, which were based on the International Classification of Disease (ICD) codes  revised in 
1995.12 Because primary liver cancer, according to Code ICD-10 (C22), include intrahepatic cholangiocarcinoma 
as well as HCC, a more informative analysis using strict definition (C22.0 and C22.9) would be needed for 
more accurate statistics for HCC in Korea. 
HCC is rare among people under the age of 30, but its incidence progressively increases from the 4th up 
to the 7th decade.13 A crude incidence of HCC, according to age, peaks in the late sixth decade in men and 
in the early seventh decade in women,7,14,15 but age-specific incidence rate of HCC reaches a peak in the early 
8th decade, which differs from the incidence pattern in Japan or Western countries. HBV-associated HCC occurs 
approximately 10 years earlier than HCV-associated HCC.7,16 A more prolonged exposure to HBV, which is 
vertically transmitted almost from HBsAg-positive mother in HBV-endemic area, seems to be a possible ex-
planation for relatively earlier occurrence of HCC. Though the incidence rate of HCC shows a slightly decreased 
pattern in the recent years, the distribution of peak crude incidence appears to be shifting toward a younger 
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Figure 1. Incidence of major malig-
nancy in Korea (2003~2005). The ma-
jority of primary liver cancer is hep-
atocellular carcinoma (HCC), and the 
remainder includes cholangiocarcinoma, 
Klatskin tumor, mixed HCC and chol-
angiocarcinoma, and hepatoblastoma in 
the order of their incidence. 
Figure 2. Risk factors for the develop-
ment of HCC in Korea. Liver cirrhosis 
is the most important and independent 
risk factor.
age. At the age of peak incidence of HCC in Korea, HCC develops approximately 4.2~5.9 times more com-
monly in men than in women, which might be related to the fact that chronic liver disease is more prevalent 
in men than women.7,13,15-17
Risk factors 
Annual detection rate of HCC in patients with chronic liver disease was reported to be 1.64~4.2%.18,19 Liver 
cirrhosis, irrespective of etiology, is known to be the most important and independent risk factor for the devel-
opment of HCC. Seventy-three to eighty-five percent of patients with HCC have liver cirrhosis.16 In addition 
to liver cirrhosis, HBV, HCV, and alcohol are major risk factors for HCC in Korea. Several studies conducted 
in Korea reported that HBsAg was found in 68.8~78.6% of patients with HCC, anti-HCV in 3.2~12.4%, both 
in 0.2~1.4%, alcohol abuse in 3.1~4.9%, and underlying liver disease was cryptogenic in 5.6~10.3% (Fig. 
2).15,16,18,20,21 Also, HBsAg or anti-HCV seropositivity, age over 50 years old and male gender, esophagogastric 
varices were indicated to be the factors which increased the risk of development of HCC in patients with liver 
cirrhosis.18,22,23 The cumulative incidence rates for the development of HCC were 2.6, 6.7, 12.3, 18.8, 21.5 and 
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26.2% at 1, 2, 3, 4, 5 and 6 year, respectively, after the first esophageal variceal bleeding in cirrhotic patients.18 
HBV- or HCV-related cirrhosis was more frequently complicated by HCC than alcoholic cirrhosis with the 
5-year cumulative incidence in each group being 24, 28, and 5%, respectively.24 A recent study reported a sig-
nificantly increased incidence of cryptogenic HCC during last decade, and suggested that non-alcoholic fatty 
liver disease and its risk factors might be involved in the development of cryptogenic HCC.25 Besides, hepatitis 
B viral load itself has been reported to be a risk factor for post-treatment recurrence of HCC.26,27
Clinical characteristics 
The proportion of patients who presented with the symptoms related to HCC at the time of diagnosis was 
41.3~67.4% overall, while it was 26.7~46.7% for the cases detected during periodic surveillance, and 5~12% 
for those noticed by chance.16 The size of the tumors, when HCCs were detected, was 2~5 cm in 38.1% of 
the cases, 5~10 cm in 30.2%, huge HCC larger than 10 cm in 21.1%, while small HCC less than 2 cm only 
accounted for 10.6%.15 The cases with multiple masses (62.7%) were more common than those with a single 
mass (37.3%). Portal vein invasions were found in 31.4~39% of patients with HCC. Because the majority of 
HCC are diagnosed in the state of Child-Pugh grade A (52.1~71.2%) rather than Child class B (23.3~36.1%) 
or C (5.5~11.8%) in Korea,15,16 an efficient and organized application of nationwide surveillance program would 
enhance the chance to cure and improve the survival rate of HCC patients. There are also distinct trends; young-
er patients show a more frequent relationship with HBV rather than HCV, higher levels of α-fetoprotein, poorer 
prognosis due to more advanced tumor stages despite more preserved liver functions.14,28,29
Treatments 
Surgical treatments
At present, liver resection is the most preferred treatment modality for resectable HCCs in patients with well 
preserved liver function.30 The 5-year survival rate after curative resection is 40~50%, but 5-year recurrence 
rate reaches 75~100%.31,32 Especially, after resection of HCC which meets Milan criteria in patients with 
Child-Pugh grade A cirrhosis, overall survival rates at 1, 3, 5, and 10 years were 92%, 78%, 69%, and 52%, 
respectively, and 1-, 3-, 5-, and 10-year disease-free survival rates were 79%, 57%, 44%, and 19%, 
respectively.33 Thus, high recurrence rate is a challenge in patients with HCC who undergo liver resection. 
Various factors have been revealed to affect the recurrence of HCC after resection.34-36 Even for a huge (≥10 
cm) HCC, a curative resection appears to achieve a favorable outcome in well selected cases; a previous study 
reported 5-year disease free and overall survival rates after resection being 35.8% and 41.0%, respectively.37 
In metastatic HCC, metastasectomy with concurrent resection or local treatment for the primary HCC was re-
ported to be superior to medical treatment alone or conservative management.38-40
Neoadjuvant or adjuvant chemotherapy for HCC, which seemed inefficient previously, are now reappraised 
as potential treatment modalities with methodological advances in these fields. Neoadjuvant chemoradiation ther-
apy following surgery for unresectable HCC met with satisfactory results.41 Minimal invasive surgery has also 
been introduced to the field of liver resection for HCC, and is now developing into Robot surgery.42,43
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Liver transplantation (LT) is a feasible way, but it is usually restricted to the cases of unresectable HCC with-
in the Milan’s criteria, which are cases with single tumor less than 5 cm or multiple tumors of no more than 
three in number and less than 3 cm in size.44,45 In a study including about 312 HCC patients from 4 Korean 
institutions, the 3-year survival rate of patients (70.4% of whole series) within the Milan criteria was 89.9% 
after cadaveric donor LT (CDLT) and 91.4% after living donor LT (LDLT) excluding perioperative mortality, 
while that in patients (77.7% of whole series) who met the criteria of University of California San Francisco 
was 88.1% after CDLT and 90.6% after LDLT.46
Non-surgical treatments 
In patients who received no specific treatments for HCC, the cumulative survival rate of 6 month and 1 year 
were 17.0~37.5% and 7.0~16.6%, respectively, and the median survival period was 3~4 months, although there 
were considerable differences in Child-Pugh grades and tumor staging.17,47
Transcatheter arterial chemoembolization (TACE) is a treatment modality applied most frequently to the pa-
tients with HCC in Korea.48 In patients with the liver function of Child-Pugh grade A or B, the cumulative 
survival rates were 66.3~64.5% and 16.5~13.9% at 1 and 3 years after TACE, respectively, which were much 
better than those in grade C patients.17 TACE was also reported to have a survival benefit even in a portion 
of HCC patients with portal vein thrombosis.49,50 Multinodular type and portal vein thrombosis were analyzed 
to be the factors affecting the recurrence after TACE.51
Percutaneous ethanol injection therapy (PEIT) and radiofrequency ablation (RFA) are generally accepted to 
be effective locoregional ablation therapies in HCC less than 3 cm in size and less than 4 in number. After 
a complete ablation of tumors by PEIT, the cumulative 1-, 2-, and 3-year overall survival rates were 73%, 50%, 
and 37%, respectively.52 Tumor multiplicity, size, and remaining hepatic reserve were reported to be the factors 
associated with local recurrence and tumor-free survival after PEIT.52,53 RFA has recently been shown to have 
the therapeutic results comparable to those of surgical resection for HCC.54 Overall survival rates were reported 
to be 89~95.8%, 67.4~86.8%, and 46.4~80.0% at 1, 2, and 3 years, respectively, and the mean survival duration 
was 45 months. Child-Pugh grade, platelet count, serum albumin and bilirubin levels, and tumor size were the 
independent prognostic factors for local recurrence and survival after RFA.54-56 
In addition, antiviral therapy has been found to have beneficial effects in aspects of on-treatment liver func-
tion and post-treatment recurrence in patients with HBV-related HCC.57
Besides the treatment modalities mentioned above, hepatic arterial infusion chemotherapy, systemic chemo-
therapy, radiotherapy and multi-directional combined therapy have been applied to the patients with advanced 
HCC, who were not candidates of effective treatments or failed to respond to previous treatments, as optional 
or salvage treatment modality.58-65 
Mortality and survival
Three major causes of death in Korea have been malignancy, cerebrovascular accidents, and cardiovascular 
diseases during the last twenty years. Since 1980, when Korea Central Cancer Registry was introduced, the mor-
tality rate due to cancer has been gradually increasing.66 Annual reports of vital statistics of Korea reported that 
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Figure 3. Survival rate of hepatocellular 
carcinoma in Korea. The overall median 
survival time was 14.3 months.
2006’s death toll was 65,909, 27.0% of which was caused by cancer. Among the deaths due to malignant neo-
plasms, the death from primary liver cancer has ranked second (16.6%), following lung cancer (21.4%). 
Although the incidence rate of primary liver cancer shows a modestly decreasing pattern, the crude mortality 
rate increased slightly from 24 per 100,000 persons in 1983, 30.0 per 100,000 in 1989, 33.5 per 100,000 persons 
in 1995, 32.5 per 100,000 persons in 2001 to 34.5 per 100,000 persons in 2007.66
Nationwide survey for the survival rate of patients with primary liver cancer was performed with 1,151,789 
subjects who were diagnosed with cancer and registered in the database of Korea Central Cancer Registry be-
tween 1993 and 2005. During this period, 5-year survival rate in these cancer patients was 47.4%, with the 
survival rate in female patients (58.4%) being higher than that in the males (38.6%), which reflects the relatively 
high survival rates of breast, cervix and thyroid cancer. In men, 5-year survival rates of primary liver cancer 
have increased almost 2-folds from 9.9% during the period of 1993~1995, 12.9% during 1996~2000 to 18.8% 
during 2001~2005. These survival data, however, are by far lower than those (43.0% during 1993~1995, 46.9% 
during 1996~2000, 57.0% during 2001~2005) of stomach cancer, the most frequent malignancy in Korean male. 
In women, 5-year survival rates of primary liver cancer have also modestly increased from 13.6% during the 
period of 1993~1995, 14.2% during 1996~2000 to 19.0% during 2001~2005. These survival figures are still in-
ferior to those (78.0% during 1993~1995, 83.2% during 1996~2000, 87.3% during 2001~2005) of breast cancer, 
the most frequent malignancy in Korean female.67 
Overall, the survival of HCC patients remains very poor. In a recent report from the National Cancer Center 
Hospital, the 1-, 2-, 3-, and 4-year survival rates of HCC were 53.8%, 40.0%, 31.4%, and 25.7%, respectively 
(Fig. 3.), and the overall median survival period was 14.3 months. But the survival rates were exceedingly dif-
ferent between subgroups according to the degree of the remaining hepatic reserve (Child-Pugh grade), tumor 
stage (modified 5th UICC TNM staging), and treatment modalities.15
There were several reasons for the prognosis of HCC being poorer than that of other malignancy. First, tumor 
progression and invasion are fast because of the aggressive biologic behavior of HCC itself. Second, most pa-
tients with HCC have chronic liver diseases such as cirrhosis, which could hinder the curative managements 
of HCC. Third, many cases of HCC are diagnosed in their advanced stages, which means a lower chance for 
curative treatments. Treatment modalities, Child-Pugh grade, TNM staging, portal vein thrombosis, serum α- fe-
toprotein level, and the number and type of tumor were analyzed as independent prognostic factors for HCC.15,47 
Causes of death in HCC patients in Korea, irrespective of treatment modality, are liver failure, gastrointestinal 
bleeding and infection, in the order of their incidences.17,47 
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National efforts to reduce the occurrence of HCC 
In 1980, Ministry of Health and Welfare and the National Cancer Center performed a “National Cancer 
Registration Program”, which intended to promote a national effort to exactly compute the statistics for the an-
nual report of cancer prevalence in Korea. In 1996, “National R&D Program for Cancer Control” was started 
to support the R&D activities of the industry, academia and research institutes. In 2001, in conjunction with 
the National Cancer Center, the Korean Liver Cancer Study Group (KLCSG) made recommendations for the 
early detection of HCC so curative treatments could be applied as early as possible. In 2003, “National Cancer 
Screening Program”, which was initially introduced for stomach, cervix, and breast cancer in 1999, was ex-
tended to HCC for high-risk subjects with low socioeconomic status. Practice guideline for diagnosis and treat-
ment of HCC, which was enacted in 2004,30 was revised by the efforts of KLCSG and the National Cancer 
Center in 2009.68 At present, the National Cancer Control Institute, which was reorganized in 2005, is working 
with the aim to be a world-class cancer control policy institute. Besides, nationwide screening for HBsAg and 
anti-HCV for the whole population, universal vaccination for HBV in children, routine screening for HBsAg 
and anti-HCV of all blood products are all preventive efforts currently enforced in Korea to reduce the incidence 
of HCC. 
Future perspectives 
The reports from Korea, in comparison with those from other countries such as Japan69 and the United 
States,70 show distinct differences in the features of HCC, including its incidence, risk factors, survival and mor-
tality rates. International collaboration between Korea and other countries for clinico-epidemiologic research 
should be encouraged to precisely understand the reasons for these differences, and eventually to provide the 
specific measures for managing HCC in diverse etiologic situations.
Recently, sorafenib, a potent multikinase inhibitor, was introduced into the treatment of advanced HCC as 
a molecular targeted therapy,71-74 but its therapeutic effect was limited and had a room for more improvement. 
Definite clarification in the molecular and cellular levels of hepatitis virus-associated hepatocellular carcino-
genesis might be necessary to provide insights into the advanced therapeutic and preventive approaches for HCC 
in Korea, where the majority of HCC originate from chronic HBV and HCV infections. 
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